Since 2007, the blockbuster cholesterol pills Zetia and Vytorin have been under a cloud as many doctors questioned their effectiveness at preventing heart attacks – and those questions have caused prescriptions of the pills to fall by more than 50%. Today, that cloud lifts.
An 18,000-patient trial shows that Vytorin, which combines Zetia and the older drug simvastatin, prevented more heart attacks, strokes, and other heart problems than simvastatin alone, exonerating the drugs. Merck revealed that the study succeeded in a press release this morning.
Also read: When Doing Good Ends Badly for CEOs